PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(™) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU

WALTHAM, Mass., Dec. 17, 2018 /PRNewswire/ -- PharmaEssentia, a global biopharmaceutical company focused on developing and commercializing novel treatments for treatment of rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, r...